Copper Rock Capital Partners LLC lowered its stake in shares of Hill-Rom Holdings, Inc. (NYSE:HRC) by 3.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 316,051 shares of the medical technology company’s stock after selling 9,999 shares during the period. Hill-Rom accounts for 2.2% of Copper Rock Capital Partners LLC’s holdings, making the stock its 2nd biggest position. Copper Rock Capital Partners LLC owned about 0.47% of Hill-Rom worth $27,398,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors also recently made changes to their positions in the company. Oakbrook Investments LLC raised its stake in Hill-Rom by 34.5% in the 3rd quarter. Oakbrook Investments LLC now owns 8,967 shares of the medical technology company’s stock valued at $846,000 after acquiring an additional 2,300 shares during the period. Marshall Wace LLP bought a new stake in Hill-Rom in the 2nd quarter valued at $10,392,000. Vanguard Group Inc raised its stake in Hill-Rom by 0.6% in the 3rd quarter. Vanguard Group Inc now owns 5,916,827 shares of the medical technology company’s stock valued at $558,549,000 after acquiring an additional 34,369 shares during the period. Millennium Management LLC raised its stake in Hill-Rom by 32.3% in the 2nd quarter. Millennium Management LLC now owns 583,635 shares of the medical technology company’s stock valued at $50,975,000 after acquiring an additional 142,654 shares during the period. Finally, LSV Asset Management bought a new stake in Hill-Rom in the 3rd quarter valued at $715,000. Institutional investors own 82.55% of the company’s stock.
A number of research analysts have commented on the company. ValuEngine lowered Hill-Rom from a “buy” rating to a “hold” rating in a report on Thursday, October 4th. Morgan Stanley upped their price objective on Hill-Rom from $95.00 to $100.00 and gave the company an “equal weight” rating in a report on Thursday, October 11th. Barclays assumed coverage on Hill-Rom in a report on Monday, October 15th. They issued an “equal weight” rating and a $95.00 price objective on the stock. Raymond James upped their price objective on Hill-Rom from $100.00 to $105.00 and gave the company an “outperform” rating in a report on Monday, November 5th. Finally, Zacks Investment Research reaffirmed a “buy” rating and issued a $106.00 price objective on shares of Hill-Rom in a report on Tuesday, November 13th. Five equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $102.67.
In other news, SVP Andreas G. Frank sold 7,454 shares of the stock in a transaction on Wednesday, November 28th. The stock was sold at an average price of $95.76, for a total transaction of $713,795.04. Following the sale, the senior vice president now directly owns 27,224 shares of the company’s stock, valued at approximately $2,606,970.24. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Corporate insiders own 1.90% of the company’s stock.
Shares of HRC traded up $1.40 during trading hours on Wednesday, hitting $91.98. 14,075 shares of the company were exchanged, compared to its average volume of 729,940. The firm has a market cap of $5.91 billion, a P/E ratio of 19.37, a price-to-earnings-growth ratio of 1.22 and a beta of 0.96. Hill-Rom Holdings, Inc. has a fifty-two week low of $78.16 and a fifty-two week high of $99.81. The company has a debt-to-equity ratio of 1.11, a quick ratio of 1.30 and a current ratio of 1.74.
Hill-Rom (NYSE:HRC) last released its earnings results on Friday, November 2nd. The medical technology company reported $1.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.51 by $0.12. The company had revenue of $759.20 million for the quarter, compared to analyst estimates of $750.90 million. Hill-Rom had a return on equity of 21.10% and a net margin of 8.86%. Hill-Rom’s quarterly revenue was up 2.8% on a year-over-year basis. During the same period in the prior year, the firm posted $1.32 EPS. On average, research analysts predict that Hill-Rom Holdings, Inc. will post 5.13 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which was paid on Monday, December 31st. Stockholders of record on Friday, December 14th were issued a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a dividend yield of 0.87%. The ex-dividend date of this dividend was Thursday, December 13th. Hill-Rom’s dividend payout ratio (DPR) is currently 16.84%.
ILLEGAL ACTIVITY WARNING: “Copper Rock Capital Partners LLC Reduces Stake in Hill-Rom Holdings, Inc. (HRC)” was originally published by Fairfield Current and is the sole property of of Fairfield Current. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this story can be viewed at https://www.fairfieldcurrent.com/news/2019/01/09/copper-rock-capital-partners-llc-reduces-stake-in-hill-rom-holdings-inc-hrc.html.
Hill-Rom Company Profile
Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It operates in three segments: Patient Support Systems, Front Line Care, and Surgical Solutions. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other patient mobility devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.
Further Reading: What is a put option?
Receive News & Ratings for Hill-Rom Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Hill-Rom and related companies with MarketBeat.com’s FREE daily email newsletter.